Compare UBXG & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | UBXG | BOLD |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 36.5M |
| IPO Year | 2021 | 2024 |
| Metric | UBXG | BOLD |
|---|---|---|
| Price | $0.40 | $1.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 885.2K | 374.5K |
| Earning Date | 06-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $0.96 |
| 52 Week High | $4.49 | $1.72 |
| Indicator | UBXG | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 31.33 | 63.36 |
| Support Level | N/A | $1.12 |
| Resistance Level | $2.12 | N/A |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 0.11 | 50.00 |
U-BX Technology Ltd focuses on providing value-added services using artificial intelligence-driven technology to businesses in the insurance industry, including insurance carriers and brokers. Its main offerings include three services/products: digital promotion services, risk assessment services, and value-added bundled benefits. The PRC operating entities help their institutional clients gain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or clients' promotion time on these channels. U-BX Beijing developed a unique algorithm named the Magic Mirror. The majority of revenue comes from digital promotion services. Geographically, all of the company's revenue is derived from Mainland China.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.